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Introduction
Colorectal cancer (CRC) is a disease of global concern, as it is the fourth frequently diagnosed malignancy overall and the second leading cause of cancer-related death worldwide. 1 Moreover, the incidence and mortality of CRC appear to be increasing in Asia, because of a "westernized" lifestyle with increased fat intake and sedentary behavior. 2, 3 Among various risk factors, obesity is considered as a significant risk factor for CRC and colorectal adenoma. [4] [5] [6] Although the exact mechanisms have not been fully identified, several studies have demonstrated that the pattern of bodyfat distribution may be more important than general adiposity such as the body mass index (BMI). Metabolically active visceral adipose tissue can create a pro-inflammatory and insulin-resistant condition. [7] [8] [9] In addition, it has been hypothesized that metabolic abnormalities, including insulin resistance, play roles as links between obesity and colorectal neoplasia. 2, 10 Recent interest has focused on age-related changes in body composition referred to as sarcopenia. Sarcopenia is a pathological condition characterized by the progressive loss of muscle mass and increased amount of visceral fat, despite a relatively constant bodyweight. 11 Recent studies have shown that sarcopenia is associated with several diseases, as well as with poor morbidity and mortality outcomes. [12] [13] [14] [15] [16] [17] [18] The pathophysiological backgrounds of sarcopenia, such as accumulation of visceral fat, metabolic abnormalities, and decreased physical activity, are similar to those of colorectal neoplasia. However, the role of sarcopenia in colorectal neoplasia remains unclear. Therefore, we examined the association between sarcopenia and the risk of colorectal neoplasia. Furthermore, we investigated whether sarcopenia can cause colorectal neoplasia through metabolic risk factors.
Methods
Study population. We conducted a cross-sectional study of healthy adults, who underwent routine health screening that included colonoscopy. The participants underwent health check-up at the Center for Health Promotion, Samsung Medical Center, Seoul, South Korea. Considering as our objective, we included participants aged 50 years and older who underwent screening colonoscopy and anthropometric measurements, including height, weight, and appendicular skeletal muscle mass (ASM) (n = 20 131). We excluded participants who met any of the following criteria: history of colonoscopy, polypectomy, or colorectal surgery; and presence of inflammatory bowel disease. Additionally, we excluded participants with incomplete colonoscopy, poor bowel preparation, or missing data. Finally, 14 024 healthy participants who underwent screening colonoscopy and anthropometric measurements were included in this study. The study was approved by the Institutional Review Board of Samsung Medical Center, and the requirement for informed consent was waived as we only used de-identified data routinely collected during health-screening visits.
Data collection. The comprehensive health-screening program included anthropometric measurements, endoscopy, serum biochemical measurements, assessment of demographic characteristics, and a self-administered health questionnaire regarding smoking habits, alcohol consumption, physical activity, personal medical history, and family history of cancer. 19 Smoking status was categorized as never, former, or current smoker. Alcohol consumption status was categorized as mild (≤ 10 g/day) or modest (> 10 g/day). Regular exercise was defined as exercising ≥ 3 times/week at moderate intensity. Weight and height were measured bare feet while wearing light clothing. Weight and height were determined to the nearest 0.1 kg and 0.1 cm, respectively. BMI was calculated as weight (kg) divided by height (m) squared (kg/m 2 ). Blood pressure was measured, using an automated blood pressure monitor (Dinamap PRO 100; GE Healthcare, Milwaukee, WI, USA) with the participant in the seated position after > 5 min of quiet rest.
After a ≥ 12-h fast, blood samples were collected in the morning and analyzed in the hospital's clinical laboratory. Serum glucose levels were measured using the hexokinase/glucose-6-phosphate dehydrogenase method with the Hitachi 7600, Modular Dp-110 autoanalyzer (Hitachi, Tokyo, Japan). Total cholesterol, triglycerides, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol (HDL-C) were measured using enzymatic colorimetric and liquid-selective detergent methods with the Hitachi 7600 autoanalyzer (Hitachi).
Definitions of sarcopenia and obesity. Bioelectrical impedance analysis (BIA) was performed using Inbody 720 (Biospace, Seoul, Korea) to estimate ASM. BIA is a convenient and cost-effective tool for assessing impedance in various body segments, including the limbs and trunk, in order to estimate ASM. 20 In this study, ASM was calculated as the sum of the lean muscle masses of the bilateral upper and lower extremities. The skeletal muscle mass index, a validated measure of sarcopenia, was calculated as follows: the skeletal muscle mass index (%) = ASM (kg)/bodyweight (kg) × 100. 21 Sarcopenia was defined as a skeletal muscle mass index beyond two standard deviations more than the sex-specific values measured in young healthy adults, according to national health examinations in Korea (skeletal muscle mass index < 29.1 in men and < 23.0 in women). 22 General obesity was defined according to the Asianspecific criteria based on BMI (BMI ≥ 25 kg/m 2 ). Visceral (central) obesity was defined based on waist circumference (≥ 90 cm in men and ≥ 85 cm in women for Asians).
Colonoscopies. Experienced board-certified gastroenterologists performed colonoscopies using an Olympus CF-Q260AI or CF-Q260AL colonoscope (Olympus Medical Systems, Tokyo, Japan) after bowel preparation with 4 L of polyethylene glycol solution (CoLyte; Taejun, Seoul, South Korea). The following information was entered in the electronic medical record after colonoscopy: number of polyps, locations and sizes of polyps, time and results of the last colonoscopy, family history of CRC, bowel preparation (excellent/good/fair/poor), and completeness of colonoscopy. Endoscopists assessed the location of colorectal neoplasia and estimated the size of each lesion using open biopsy forceps. Biopsy samples were sent to the pathology department, where qualified pathologists assessed the histopathology of the lesions. 23 Advanced colorectal neoplasia was defined as any adenoma larger than 1 cm, any adenoma with a villous component, high-grade dysplasia, or invasive CRC.
Statistical analysis. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for advanced colorectal neoplasia according to sarcopenia status. The multivariable model was selected by backward stepwise selection method based on Akaike information criterion. The candidate factors included age, sex, obesity status based on BMI ≥ 25, smoking status, alcohol consumption, regular exercise, sarcopenia status, and metabolic parameters (visceral obesity based on waist circumference, systolic blood pressure, antihypertensive medication, fasting glucose level, hypoglycemic medication, HDL-C, triglycerides level, and dyslipidemia medication). Multivariable model 1 was adjusted for traditional risk factors and confounders such as age, sex, obesity status (BMI ≥ 25), smoking status, alcohol intake, regular exercise, and family history of CRC. We fitted an additional model 2 adjusted for metabolic parameters that could be potential mediators of the association between sarcopenia status and advanced colorectal neoplasia. Model 2 was adjusted for visceral obesity based on waist circumference, systolic blood pressure, antihypertensive medication, fasting glucose level, hypoglycemic medication, HDL-C, triglycerides level, and dyslipidemia medication in addition to the factors included in model 2.
In addition, we performed two types of dose-response analyses. First, we conducted a multivariable analysis based on the severity categories of sarcopenia and estimated the adjusted ORs with 95% CIs for advanced colorectal neoplasia on comparing categories with the normal category. We categorized sarcopenia into the following three groups according to severity: normal; class I sarcopenia, weight-adjusted skeletal muscle mass index between one and two standard deviations below the sex-specific values measured in young healthy adults; and class II sarcopenia, weight-adjusted skeletal muscle mass index more than two standard deviations below the sex-specific values measured in young healthy adults. We then estimated the adjusted ORs with 95% CIs associated with a weight-adjusted skeletal muscle mass index decrease of 1% using ASM/weight as a continuous variable in the logistic regression model. A P value < 0.05 was considered statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.4.3 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
The mean (standard deviation) age of the 14 024 study participants was 56.5 (5.6) years. The baseline characteristics of the participants are shown in Table 1 . The participants were categorized into the following two groups according to the presence of sarcopenia class II: non-sarcopenia group (12 348 [88%] ) and sarcopenia group (1676 [12%]). The baseline characteristics were significantly different according to the sarcopenic status. Participants in the sarcopenia group were older, were more likely to be male and not exercise regularly, had higher BMI, waist circumference, blood pressure, triglyceride levels, and fasting glucose levels, and had lower ASM/weight and HDL-C values when compared with participants in the non-sarcopenia group. Additionally, the sarcopenia group had a higher proportion of current smokers and modest alcohol consumers than the non-sarcopenia group. Thus, the sarcopenia group had a higher proportion of patients with metabolic syndrome than the non-sarcopenia group.
Among the 14 024 participants, the prevalences of any colorectal neoplasia and advanced colorectal neoplasia were 39.9% (n = 4322) and 7.0% (n = 754), respectively. According to the status of sarcopenia, the prevalences of advanced colorectal neoplasia were 5.8% in normal group, 8.1% in class I sarcopenia group, and 10.9% in class II sarcopenia group (Fig. 1) . The prevalences of any colorectal neoplasia were 35.4% in normal group, 46.7% in class I sarcopenia group, and 50.9% in class II sarcopenia group. Table 2 shows the results of univariable and multivariable logistic regression analyses for advanced colorectal neoplasia. Sarcopenia was significantly associated with the risks of advanced colorectal neoplasia (OR, 1.31; 95% CI, 1.06-1.61). In the multivariable analysis, age, male sex, current smoking, modest alcohol intake, family history of CRC, and visceral obesity were significantly associated with advanced colorectal neoplasia.
The risks of advanced colorectal neoplasia differed according to the severity of sarcopenia. Table 3 shows the dose-response relationship between sarcopenia and advance colorectal neoplasia. In crude model, the ORs (95% CIs) for advanced colorectal neoplasia on comparing participants with class I sarcopenia and class II sarcopenia to those without sarcopenia were 1.44 (1.20-1.71) and 1.99 (1.63-2.43), respectively. In multivariable model 1 adjusted for age, sex, obesity status, smoking status, alcohol intake, regular exercise, and family history of CRC, the adjusted ORs (95% CIs) for advanced colorectal neoplasia on comparing participants with class I sarcopenia and class II sarcopenia to those without sarcopenia were 1.14 (0.94-1.36) and 1.51 (1.23-1.85), respectively. After adjustments for metabolic parameters (model 2), the association between sarcopenia and advanced colorectal neoplasia was attenuated, but it persisted. In the dose-response analysis, increasing sarcopenia severity showed Values are expressed as means ± standard deviation, percentages, or median (interquartile range). ASM, appendicular skeletal muscle mass; BMI, body mass index; CRC, colorectal cancer; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure.
a graded dose-response relationship with advanced colorectal neoplasia. Further, the adjusted OR associated with a 1% decrease on the introduction of ASM/weight as a continuous variable in the regression models was 1.04 (1.01-1.07) for advanced colorectal neoplasia in model 2.
Discussion
In this large, cross-sectional study of an asymptomatic screening population undergoing first-time colonoscopy, we found a significant association between sarcopenia and colorectal neoplasia. The magnitude of the association was stronger for advanced colorectal neoplasia. The association was independent of traditional risk factors for CRC, including obesity and metabolic risk factors. Furthermore, we found that increasing sarcopenia severity showed a positive and graded dose-response relationship with advanced colorectal neoplasia. All these findings indicate that sarcopenia and its severity are closely associated with the risk of colorectal neoplasia independent of traditional risk factors. Close attention should be paid to the increased risk of colorectal neoplasia in individuals with sarcopenia. Sarcopenia has become an important concept for understanding the impact of aging on health outcomes. This condition is a physiological symptom of aging, and there is growing evidence that low muscle mass is associated with a number of disorders. [12] [13] [14] [15] [16] [17] [18] Sarcopenia is common in elderly populations and contributes to functional limitations, disabilities, and frailty. 24, 25 Furthermore, several previous studies have found that sarcopenia is associated with increased risks of several disorders, such as cardiovascular disease and metabolic syndrome, and morbidity/mortality. [12] [13] [14] [15] [16] [17] [18] Only two studies have reported that sarcopenia is a risk factor for colorectal neoplasia. 26, 27 The present study further supports that sarcopenia is a significant risk factor for colorectal neoplasia, especially advanced neoplasia. In addition, we showed that sarcopenia severity is associated with the risk of advanced colorectal neoplasia. Previous evidence has shown a significant association between colorectal neoplasia and obesity, especially central obesity. [28] [29] [30] [31] [32] Central obesity, which is typically measured in terms of waist circumference, waist-hip ratio, or visceral adiposity, seems to be a more important predictor of colorectal neoplasia than is general obesity. [28] [29] [30] [31] [32] The important changes in body composition, including a decline in skeletal muscle and an increase in bodyfat, especially abdominal visceral fat, are noticed in individuals with sarcopenia. 15, [33] [34] [35] In the study, even after adjusting for obesityrelated parameters such as obesity based on BMI and central obesity based on waist circumference, sarcopenia was still a significant predictor of advanced colorectal neoplasia. We found that sarcopenia might be a more harmful condition for advanced colorectal neoplasia than general obesity.
In this study, we conducted an analysis based on the severity categories of sarcopenia and categorized sarcopenia into three groups (normal, class I sarcopenia, and class II sarcopenia) according to severity. We observed a trend of increasing ORs for advanced colorectal neoplasia among those with severe sarcopenia. However, among those with mild sarcopenia, the association was not strong. Further, with the skeletal muscle mass index modeled as a continuous variable, we noted an inverse relationship between the skeletal muscle mass index and the risk of colorectal neoplasia in a dose-dependent manner. Each 1% decrease in the skeletal muscle mass index predicted a 4.0% increase in the risk of advanced colorectal neoplasia (Model 2 in Table 3) .
Although the precise mechanisms that link low muscle mass and colorectal neoplasia are not yet fully elucidated, multiple mechanisms have been implicated in this association. Physical inactivity is itself considered as a risk factor for colorectal neoplasia, and it can decrease muscle mass. 36, 37 Thus, a link between low muscle mass and colorectal neoplasia can be established. Important changes in body composition associated with sarcopenia, including a decline in skeletal muscle and an increase in bodyfat, especially abdominal visceral fat, are also significant contributing factors to the development of colorectal neoplasia. In addition, the skeletal muscle is the primary tissue for insulin-mediated glucose disposal. Therefore, low skeletal muscle mass in patients with sarcopenia reduces insulin-mediated glucose uptake and, subsequently, induces insulin resistance. 38, 39 The insulin-resistant condition can elevate insulin and insulin-like growth factor, which, in turn, may promote the growth of colorectal neoplasia. [40] [41] [42] Moreover, a recent study, using data from the National Health and Nutrition Examination Survey III, showed that sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia. 43 Additionally, sarcopenia-associated loss of skeletal muscle mass and gain of visceral adiposity have been shown to be positively associated with blood pressure, triglyceride levels, hyperglycemia, and a number of other metabolic syndrome components. 15, 38, 39 Strong evidence also supports the association of metabolic syndrome with colorectal neoplasia. 19, 23, 44 Sarcopenia-induced chronic inflammation is another potential mechanism for colorectal neoplasia. Age-related, chronic, lowgrade inflammation is recognized as an important causative factor for sarcopenia, and the findings of cross-sectional and longitudinal studies support the association between inflammation and sarcopenia. 45 Adipocytokines, such as tumor necrosis factor-α and interleukin-6, are mainly involved in sarcopenia-associated inflammation. 45 Several studies have suggested that tumor necrosis factor-α, interleukin-6, adiponectin, leptin, and other pro-inflammatory cytokines play roles in the development of colorectal neoplasia. 46, 47 However, further research is needed to understand the underlying mechanisms of insulin resistance, inflammation, and metabolic syndrome associated with sarcopenia and their roles in colorectal neoplasia.
This study has several strengths. Its large sample size, the inclusion of first-time colonoscopies, and the adjustment of potential confounding factors of colorectal neoplasia allowed minimization of temporal bias. Additionally, high-quality, standardized anthropometric measurements were used. Moreover, an epidemiological questionnaire regarding lifestyle factors was incorporated, and various laboratory studies were performed. 
Sarcopenia and colorectal neoplasia
Nevertheless, several limitations need to be considered when interpreting the results of our study. First, the cross-sectional design of this study makes it impossible to determine any causality for the association. Second, although BIA is a convenient and safe method for assessing the skeletal muscle mass index, it is not the gold standard approach. The gold standards remain dual-energy X-ray absorptiometry, computed tomography, and magnetic resonance imaging. However, several studies have validated the use of BIA when compared with either absorptiometry or magnetic resonance imaging, and these studies reported that BIA provides an accurate estimate of the skeletal muscle mass index. 20, 21, 48, 49 Another limitation of BIA is that it cannot provide information on muscle quality, such as gait speed and grip strength. These characterizations allow the description of sarcopenia in a functional way and not solely on the basis of muscle mass. Thus, our findings may not be generalizable to other populations. Further investigation is needed to clarify the association between colorectal neoplasia and sarcopenia, using more strict definition based on both muscle mass and muscle functions.
In conclusion, this study showed that sarcopenia and its severity are closely associated with the risk of any colorectal neoplasia and advanced colorectal neoplasia. The association was independent of traditional risk factors, supporting low muscle mass itself as a risk factor for colorectal neoplasia. Thus, clinician should be aware of the increased risk of colorectal neoplasia in individuals with sarcopenia, especially those with severe sarcopenia. The risk of advanced colorectal neoplasia appears to be mediated by metabolic risk factors. Further longitudinal studies are needed to confirm our findings and to elucidate the causal relationship between sarcopenia and colorectal neoplasia.
